跳至主要内容
临床试验/PACTR202109777317416
PACTR202109777317416已完成未知

Myocardial Protection With Histidine-Tryptophan- Ketoglutarate (HTK) Solution in Comparison With Hypothermic Hyperkalemic Blood (HHB) Solution in The Correction of Acyanotic Congenital Heart Diseases.

Faculty of medicine at Ain Shams university0 个研究点目标入组 60 人开始时间: 2021年9月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
1 Month(s) 至 23 Month(s)(—)
性别
All

入选标准

  • Acyanotic congenital heart diseases undergoing total repair under cardiopulmonary bypass.
  • Aged from 6 months to 2 years of both sexes.
  • Scheduled for elective operations.

排除标准

  • Reoperation.
  • Scheduled for palliative surgeries.
  • Undergoing emergency surgeries.
  • Patients with reduced left ventricular function, determined by left ventricular ejection fraction less than 40%.
  • Patients with renal or liver impairment, determined by elevated creatinine levels or liver enzymes ‘AST and ALT’ more than normal values for age.
  • Patients with any neurological dysfunction as epilepsy and cerebral palsy (CP).

研究者

相似试验